Systemic and Mucosal Immune Responses to Cryptosporidium—Vaccine Development

Current Tropical Medicine Reports

Volumn 2, Issue 3, 2015, Pages 171-180

  Ludington, Jacob G ^a,b   Ward, Honorine D ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cryptosporidium; Immune response; Mucosal; Vaccine

Indexed keywords

CHEMOKINE; CRYPTOSPORIDIUM VACCINE; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; PARASITE ANTIGEN; PEPTIDES AND PROTEINS; POLYPEPTIDE ANTIBIOTIC AGENT; PROTOZOAL VACCINE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DENDRITIC CELL; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; LIFE CYCLE; MACROPHAGE; MAST CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84988390931     PISSN: None     EISSN: 21963045     Source Type: Journal    
DOI: 10.1007/s40475-015-0054-y     Document Type: Review

References (112)

1. Striepen B. Parasitic infections: time to tackle cryptosporidiosis. Nature. 2013;503(7475):189–91.
2. Leav BA, Mackay M, Ward HD. Cryptosporidium species: new insights and old challenges. Clin Infect Dis. 2003;36(7):903–8.
3. Collinet-Adler S, Ward HD. Cryptosporidiosis: environmental, therapeutic, and preventive challenges. Eur J Clin Microbiol Infect Dis. 2010;29(8):927–35.
4. Checkley W, White Jr AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen X, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15(1):85–94.
5. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385(9966):430–40.
6. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case–control study. Lancet. 2013;382(9888):209–22.
7. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis. 2012;25(5):555–63.
8. O’Connor RM, Shaffie R, Kang G, Ward HD. Cryptosporidiosis in patients with HIV/AIDS. AIDS. 2011;25(5):549–60.
9. Hlavsa MC, Roberts VA, Anderson AR, Hill VR, Kahler AM, Orr M, et al. Surveillance for waterborne disease outbreaks and other health events associated with recreational water—United States, 2007–2008. MMWR Surveill Summ. 2011;60(12):1–32.
10. Hlavsa MC, Roberts VA, Kahler AM, Hilborn ED, Wade TJ, Backer LC, et al. Recreational water-associated disease outbreaks—United States, 2009–2010. MMWR Morb Mortal Wkly Rep. 2014;63(1):6–10.
11. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002;8(2):225–30.
12. Cabada MM, White Jr AC. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis. 2010;23(5):494–9.
13. Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. 2007;1:CD004932.
14. Tzipori S, Ward H. Cryptosporidiosis: biology, pathogenesis and disease. Microbes Infect. 2002;4(10):1047–58.
15. Smith HV, Nichols RA, Grimason AM. Cryptosporidium excystation and invasion: getting to the guts of the matter. Trends Parasitol. 2005;21(3):133–42.
16. Wetzel DM, Schmidt J, Kuhlenschmidt MS, Dubey JP, Sibley LD. Gliding motility leads to active cellular invasion by Cryptosporidium parvum sporozoites. Infect Immun. 2005;73(9):5379–87.
17. Wanyiri J, Ward H. Molecular basis of Cryptosporidium-host cell interactions: recent advances and future prospects. Future Microbiol. 2006;1:201–8.
18. Barnes DA, Bonnin A, Huang JX, Gousset L, Wu J, Gut J, et al. A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion. Mol Biochem Parasitol. 1998;96(1–2):93–110.
19. Cevallos AM, Zhang X, Waldor MK, Jaison S, Zhou X, Tzipori S, et al. Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. Infect Immun. 2000;68(7):4108–16.
20. O’Connor RM, Burns PB, Ha-Ngoc T, Scarpato K, Khan W, Kang G, et al. Polymorphic mucin antigens CpMuc4 and CpMuc5 are integral to Cryptosporidium parvum infection in vitro. Eukaryot Cell. 2009;8(4):461–9.
21. Riggs MW, Stone AL, Yount PA, Langer RC, Arrowood MJ, Bentley DL. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J Immunol. 1997;158(4):1787–95.
22. Tzipori S, Griffiths JK. Natural history and biology of Cryptosporidium parvum. Adv Parasitol. 1998;40:5–36.
23. Perkins ME, Riojas YA, Wu TW, Le Blancq SM. CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages. Proc Natl Acad Sci U S A. 1999;96(10):5734–9.
24. O’Hara SP, Chen XM. The cell biology of cryptosporidium infection. Microbes Infect. 2011.
25. Borad A, Ward H. Human immune responses in cryptosporidiosis. Future Microbiol. 2010;5:507–19.
26. McDonald V, Korbel DS, Barakat FM, Choudhry N, Petry F. Innate immune responses against Cryptosporidium parvum infection. Parasite Immunol. 2013;35(2):55–64.
27. Wilhelm CL, Yarovinsky F. Apicomplexan infections in the gut. Parasite Immunol. 2014;36(9):409–20.
28. Mead JR. Prospects for immunotherapy and vaccines against Cryptosporidium. Hum Vaccine Immunotherapeut. 2014;10(6):1505–13.
29. Jr. RBJ. An overview of the innate immune system. 2015.
30. Pantenburg B, Dann SM, Wang HC, Robinson P, Castellanos-Gonzalez A, Lewis DE, et al. Intestinal immune response to human Cryptosporidium sp. infection. Infect Immun. 2008;76(1):23–9.
31. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14(3):141–53.
32. O’Hara S, Tietz Bogert PS, Trussoni CE, Chen X, Larusso NF. Tlr4 Promotes Cryptosporidium parvum clearance in a mouse model of biliary cryptosporidiosis. J Parasitol. 2011.
33. Barrier M, Lacroix-Lamande S, Mancassola R, Auray G, Bernardet N, Chausse AM, et al. Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of cryptosporidium parvum infection in neonatal mice. J Infect Dis. 2006;193(10):1400–7.
34. Costa LB, Johnbull EA, Reeves JT, Sevilleja JE, Freire RS, Hoffman PS, et al. Cryptosporidium- malnutrition interactions: mucosal disruption, cytokines and TLR signaling in a weaned murine model. J Parasitol. 2011.
35. Lantier L, Drouet F, Guesdon W, Mancassola R, Metton C, Lo-Man R, et al. Poly(I:C)-induced protection of neonatal mice against intestinal Cryptosporidium parvum infection requires an additional TLR5 signal provided by the gut flora. J Infect Dis. 2014;209(3):457–67.
36. Perez-Cordon G, Yang G, Zhou B, Nie W, Li S, Shi L, et al. Interaction of Cryptosporidium parvum with mouse dendritic cells leads to their activation and parasite transportation to mesenteric lymph nodes. Pathogens Dis. 2014;70(1):17–27.
37. Laurent F, Eckmann L, Savidge TC, Morgan G, Theodos C, Naciri M, et al. Cryptosporidium parvum infection of human intestinal epithelial cells induces the polarized secretion of C-X-C chemokines. Infect Immun. 1997;65(12):5067–73.
38. Auray G, Lacroix-Lamande S, Mancassola R, Dimier-Poisson I, Laurent F. Involvement of intestinal epithelial cells in dendritic cell recruitment during C. parvum infection. Microbes Infect. 2007;9(5):574–82.
39. Laurent F, Kagnoff MF, Savidge TC, Naciri M, Eckmann L. Human intestinal epithelial cells respond to Cryptosporidium parvum infection with increased prostaglandin H synthase 2 expression and prostaglandin E2 and F2alpha production. Infect Immun. 1998;66(4):1787–90.
40. Carryn S, Schaefer DA, Imboden M, Homan EJ, Bremel RD, Riggs MW. Phospholipases and cationic peptides inhibit cryptosporidium parvum sporozoite infectivity by parasiticidal and non-parasiticidal mechanisms. J Parasitol. 2012;98(1):199–204.
41. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14(5):409–26.
42. Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol. 2003;74(3):448–55. This study identified a novel AMP able to target Cryptosporidium directly. Furthermore, their results suggest that Cryptosporidium is able to counteract CCL20 via miRNA-mediated downregulation.
43. Guesdon W, Auray G, Pezier T, Bussiere FI, Drouet F, Le Vern Y, et al. CCL20 displays antimicrobial activity against Cryptosporidium parvum but its expression is reduced during infection in the intestine of neonatal mice. J Infect Dis. 2015.
44. Zhou R, Gong AY, Chen D, Miller RE, Eischeid AN, Chen XM. Histone deacetylases and NF-kB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503. PLoS One. 2013;8(5):e65153.
45. Stievano L, Piovan E, Amadori A. C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol. 2004;24(3):205–28.
46. Carmolli M, Duggal P, Haque R, Lindow J, Mondal D, Petri Jr WA, et al. Deficient serum mannose-binding lectin levels and MBL2 polymorphisms increase the risk of single and recurrent Cryptosporidium infections in young children. J Infect Dis. 2009;200(10):1540–7.
47. Kelly P, Jack DL, Naeem A, Mandanda B, Pollok RC, Klein NJ, et al. Mannose-binding lectin is a component of innate mucosal defense against Cryptosporidium parvum in AIDS. Gastroenterology. 2000;119(5):1236–42.
48. Lean IS, McDonald V, Pollok RC. The role of cytokines in the pathogenesis of Cryptosporidium infection. Curr Opin Infect Dis. 2002;15(3):229–34.
49. Theodos CM. Innate and cell-mediated immune responses to Cryptosporidium parvum. Adv Parasitol. 1998;40:87–119.
50. Riggs MW. Recent advances in cryptosporidiosis: the immune response. Microbes Infect. 2002;4(10):1067–80.
51. Bedi B, McNair NN, Forster I, Mead JR. IL-18 cytokine levels modulate innate immune responses and cryptosporidiosis in mice. J Eukaryot Microbiol. 2015;62(1):44–50. This study evaluated the protective effect of IL-18 in vivo and discusses potential mechanisms.
52. McDonald V, Pollok RC, Dhaliwal W, Naik S, Farthing MJ, Bajaj-Elliott M. A potential role for interleukin-18 in inhibition of the development of Cryptosporidium parvum. Clin Exp Immunol. 2006;145(3):555–62.
53. Choudhry N, Petry F, van Rooijen N, McDonald V. A protective role for interleukin 18 in interferon gamma-mediated innate immunity to Cryptosporidium parvum that is independent of natural killer cells. J Infect Dis. 2012;206(1):117–24.
54. Ehigiator HN, McNair N, Mead JR. Cryptosporidium parvum: the contribution of Th1-inducing pathways to the resolution of infection in mice. Exp Parasitol. 2007;115(2):107–13.
55. Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med. 2002;80(3):147–62.
56. Bedi B, Mead JR. Cryptosporidium parvum antigens induce mouse and human dendritic cells to generate Th1-enhancing cytokines. Parasite Immunol. 2012;34(10):473–85.
57. Codices V, Martins C, Novo C, Pinho M, de Sousa B, Lopes A, et al. Cell phenotypic change due to Cryptosporidium parvum infection in immunocompetent mice. Acta Parasitol / Witold Stefanski Inst Parasitol, Warszawa, Poland. 2013;58(1):70–9.
58. Harp JA, Moon HW. Susceptibility of mast cell-deficient W/Wv mice to Cryptosporidium parvum. Infect Immun. 1991;59(2):718–20.
59. Barakat FM, McDonald V, Foster GR, Tovey MG, Korbel DS. Cryptosporidium parvum infection rapidly induces a protective innate immune response involving type I interferon. J Infect Dis. 2009;200(10):1548–55.
60. Bedi B, McNair NN, Mead JR. Dendritic cells play a role in host susceptibility to Cryptosporidium parvum infection. Immunol Lett. 2014;158(1–2):42–51.
61. Lantier L, Lacroix-Lamande S, Potiron L, Metton C, Drouet F, Guesdon W, et al. Intestinal CD103+ dendritic cells are key players in the innate immune control of Cryptosporidium parvum infection in neonatal mice. PLoS Pathog. 2013;9(12):e1003801. This study suggests that dendritic cells are essential to clearance of Cryptosporidium infection in neonates, an important consideration for vaccine development.
62. Dann SM, Wang HC, Gambarin KJ, Actor JK, Robinson P, Lewis DE, et al. Interleukin-15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J Infect Dis. 2005;192(7):1294–302.
63. Barakat FM, McDonald V, Di Santo JP, Korbel DS. Roles for NK cells and an NK cell-independent source of intestinal gamma interferon for innate immunity to Cryptosporidium parvum infection. Infect Immun. 2009;77(11):5044–9.
64. Korbel DS, Barakat FM, Di Santo JP, McDonald V. CD4+ T cells are not essential for control of early acute Cryptosporidium parvum infection in neonatal mice. Infect Immun. 2011;79(4):1647–53.
65. Urban Jr JF, Fayer R, Chen SJ, Gause WC, Gately MK, Finkelman FD. IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum. J Immunol. 1996;156(1):263–8.
66. Olsen L, Akesson CP, Storset AK, Lacroix-Lamande S, Boysen P, Metton C, et al. The early intestinal immune response in experimental neonatal ovine cryptosporidiosis is characterized by an increased frequency of perforin expressing NCR1 NK cells and by NCR1 CD8 cell recruitment. Vet Res. 2015;46(1):28. This study suggests that NK cells may contribute to mucosal protection via direct cytolysis.
67. Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, et al. The human mast cell: functions in physiology and disease. FronT Biosci: J Virt Lib. 2001;6:D1109–27.
68. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10(6):440–52.
69. Rhee JK, Surl CG, Kim HC. Effects of Cryptosporidium muris (strain MCR) infection on gastric mucosal mast cells in mice. Korean J Parasitol. 1997;35(4):245–9.
70. Li S, Li W, Yang Z, Song S, Yang J, Gong P, et al. Infection of cattle With Cryptosporidium parvum: mast cell accumulation in small intestine mucosa. Vet Pathol. 2013.
71. Bai J, Khaldi S, Gargala G, Baishanbo A, Francois A, Ballet JJ, et al. Effects of octreotide on jejunal hypersensitivity triggered by Cryptosporidium parvum intestinal infection in an immunocompetent suckling rat model. Neurogastroenterol Motil. 2011.
72. Codices V, Martins C, Novo C, de Sousa B, Lopes A, Borrego M, et al. Dynamics of cytokines and immunoglobulins serum profiles in primary and secondary Cryptosporidium parvum infection: usefulness of Luminex(R) xMAP technology. Exp Parasitol. 2013;133(1):106–13.
73. Zhou R, Feng Y, Chen XM. Non-coding RNAs in epithelial immunity to Cryptosporidium infection. Parasitology. 2014;141(10):1233–43.
74. Zhou R, Hu G, Liu J, Gong AY, Drescher KM, Chen XM. NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathog. 2009;5(12):e1000681.
75. Zhou R, Gong AY, Eischeid AN, Chen XM. miR-27b targets KSRP to coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum infection. PLoS Pathog. 2012;8(5):e1002702.
76. Hu G, Gong AY, Roth AL, Huang BQ, Ward HD, Zhu G, et al. Release of luminal exosomes contributes to TLR4-mediated epithelial antimicrobial defense. PLoS Pathog. 2013;9(4):e1003261. This study evaluates miRNA regulation of exosome release in the context of Cryptosporidium infection.
77. Gong AY, Hu G, Zhou R, Liu J, Feng Y, Soukup GA, et al. MicroRNA-221 controls expression of intercellular adhesion molecule-1 in epithelial cells in response to Cryptosporidium parvum infection. Int J Parasitol. 2011;41(3–4):397–403.
78. Linker K, Pautz A, Fechir M, Hubrich T, Greeve J, Kleinert H. Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR. Nucleic Acids Res. 2005;33(15):4813–27.
79. Singh I, Carville A, Tzipori S. Cryptosporidiosis in rhesus macaques challenged during acute and chronic phases of SIV infection. AIDS Res Hum Retroviruses. 2011.
80. Preidis GA, Wang HC, Lewis DE, Castellanos-Gonzalez A, Rogers KA, Graviss EA, et al. Seropositive human subjects produce interferon gamma after stimulation with recombinant Cryptosporidium hominis gp15. Am J Trop Med Hyg. 2007;77(3):583–5.
81. Pantenburg B, Castellanos-Gonzalez A, Dann SM, Connelly RL, Lewis DE, Ward HD, et al. Human CD8(+) T cells clear Cryptosporidium parvum from infected intestinal epithelial cells. Am J Trop Med Hyg. 2010;82(4):600–7.
82. Kvac M, Kodadkova A, Sak B, Kvetonova D, Jalovecka M, Rost M, et al. Activated CD8+ T cells contribute to clearance of gastric Cryptosporidium muris infections. Parasite Immunol. 2011;33(4):210–6.
83. Boulter-Bitzer JI, Lee H, Trevors JT. Molecular targets for detection and immunotherapy in Cryptosporidium parvum. Biotechnol Adv. 2007;25(1):13–44.
84. Ajjampur SS, Sarkar R, Allison G, Banda K, Kane A, Muliyil J, et al. Serum IgG response to cryptosporidium immunodominant antigen gp15 and polymorphic antigen gp40 in children with cryptosporidiosis in South India. Clin Vaccine Immunol. 2011;18(4):633–9.
85. Heimburg-Molinaro J, Priest JW, Live D, Boons GJ, Song X, Cummings RD, et al. Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides. Int J Parasitol. 2013;43(11):901–7.
86. Borad AJ, Allison GM, Wang D, Ahmed S, Karim MM, Kane AV, et al. Systemic antibody responses to the immunodominant p23 antigen and p23 polymorphisms in children with cryptosporidiosis in Bangladesh. Am J Trop Med Hyg. 2012;86(2):214–22.
87. Allison GM, Rogers KA, Borad A, Ahmed S, Karim MM, Kane AV, et al. Antibody responses to the immunodominant Cryptosporidium gp15 antigen and gp15 polymorphisms in a case–control study of cryptosporidiosis in children in Bangladesh. Am J Trop Med Hyg. 2011;85(1):97–104.
88. Wanyiri JW, Kanyi H, Maina S, Wang DE, Steen A, Ngugi P, et al. Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features, epidemiology, molecular characterization and antibody responses. Am J Trop Med Hyg. 2014;91(2):319–28. This study evaluates the protective effect of antibody responses in patients with cryptosporidiosis.
89. Lai O, Morris C, Ahmed S, Karim MM, Khan W, Ward H, et al. Serum antibody responses to polymorphic Cryptosporidium mucin antigen in Bangladeshi children with cryptosporidiosis. Am J Trop Med Hyg. 2011;85(3):464–70.
90. Mead JR. Challenges and prospects for a Cryptosporidium vaccine. Future Microbiol. 2010;5:335–7.
91. Widmer G, Lee Y, Hunt P, Martinelli A, Tolkoff M, Bodi K. Comparative genome analysis of two Cryptosporidium parvum isolates with different host range. Infect Genet Evol. 2012;12(6):1213–21.
92. Sheoran A, Wiffin A, Widmer G, Singh P, Tzipori S. Infection with cryptosporidium hominis provides incomplete protection of the host against cryptosporidium parvum. J Infect Dis. 2012;205(6):1019–23.
93. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine. 2011;29(17):3341–55.
94. Manque PA, Woehlbier U, Lara AM, Tenjo F, Alves JM, Buck GA. Identification and characterization of a novel calcium-activated apyrase from cryptosporidium parasites and its potential role in pathogenesis. PLoS One. 2012;7(2):e31030.
95. Singh I, Theodos C, Tzipori S. Recombinant proteins of Cryptosporidium parvum induce proliferation of mesenteric lymph node cells in infected mice. Infect Immun. 2005;73(8):5245–8.
96. Benitez A, Priest JW, Ehigiator HN, McNair N, Mead JR. Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis. Vaccine. 2011;29(49):9239–45.
97. Wang C, Luo J, Amer S, Guo Y, Hu Y, Lu Y, et al. Multivalent DNA vaccine induces protective immune responses and enhanced resistance against Cryptosporidium parvum infection. Vaccine. 2010;29(2):323–8.
98. Zheng J, Ren W, Pan Q, Wang Q, Elhag IA, Li J, et al. A recombinant DNA vaccine encoding C. andersoni oocyst wall protein induces immunity against experimental C. parvum infection. Vet Parasitol. 2011.
99. Yu Q, Li J, Zhang X, Gong P, Zhang G, Li S, et al. Induction of immune responses in mice by a DNA vaccine encoding Cryptosporidium parvum Cp12 and Cp21 and its effect against homologous oocyst challenge. Vet Parasitol. 2010;172(1–2):1–7.
100. Liu K, Zai D, Zhang D, Wei Q, Han G, Gao H, et al. Divalent Cp15-23 vaccine enhances immune responses and protection against Cryptosporidium parvum infection. Parasite Immunol. 2010;32(5):335–44. This study compares the protective effect of univalent and divalent Cryptosporidium DNA-based vaccines.
101. Khan KH. DNA vaccines: roles against diseases. Germs. 2013;3(1):26–35.
102. Benitez AJ, McNair N, Mead JR. Oral immunization with attenuated Salmonella enterica serovar Typhimurium encoding Cryptosporidium parvum Cp23 and Cp40 antigens induces a specific immune response in mice. Clin Vaccine Immunol. 2009;16(9):1272–8.
103. Roche JK, Rojo AL, Costa LB, Smeltz R, Manque P, Woehlbier U, et al. Intranasal vaccination in mice with an attenuated Salmonella enterica Serovar 908htr A expressing Cp15 of Cryptosporidium: impact of malnutrition with preservation of cytokine secretion. Vaccine. 2013;31(6):912–8. This study suggests that malnutrition negatively impacts mucosal immune responses to Cryptosporidium.
104. Galen JE, Zhao L, Chinchilla M, Wang JY, Pasetti MF, Green J, et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun. 2004;72(12):7096–106.
105. Manque PA, Tenjo F, Woehlbier U, Lara AM, Serrano MG, Xu P, et al. Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol. 2011;18(11):1796–802. This study uses “reverse vaccinology” to identify potential Cryptosporidium vaccine candidates.
106. Xu RG, Jia H, Terkawi MA, Xuan X, Zhang H. Immunogenicity of orally administrated recombinant lactobacillus casei Zhang expressing Cryptosporidium parvum surface adhesion protein P23 in mice. Curr Microbiol. 2011;62(5):1573–80.
107. Kim K, Weiss LM. Toxoplasma gondii: the model apicomplexan. Int J Parasitol. 2004;34(3):423–32.
108. O’Connor RM, Wanyiri JW, Wojczyk BS, Kim K, Ward H. Stable expression of Cryptosporidium parvum glycoprotein gp40/15 in Toxoplasma gondii. Mol Biochem Parasitol. 2007;152(2):149–58.
109. Shirafuji H, Xuan X, Kimata I, Takashima Y, Fukumoto S, Otsuka H, et al. Expression of P23 of Cryptosporidium parvum in Toxoplasma gondii and evaluation of its protective effects. J Parasitol. 2005;91(2):476–9.
110. Yao L, Yin J, Zhang X, Liu Q, Li J, Chen L, et al. Cryptosporidium parvum: identification of a new surface adhesion protein on sporozoite and oocyst by screening of a phage-display cDNA library. Exp Parasitol. 2007;115(4):333–8.
111. Priest JW, Kwon JP, Montgomery JM, Bern C, Moss DM, Freeman AR, et al. Cloning and characterization of the acidic ribosomal protein P2 of Cryptosporidium parvum, a new 17-kilodalton antigen. Clin Vaccine Immunol. 2010;17(6):954–65.
112. Xiao D, Yin C, Zhang Q, Li JH, Gong PT, Li SH, et al. Selection and identification of a new adhesion protein of Cryptosporidium parvum from a cDNA library by ribosome display. Exp Parasitol. 2011.